Abstract P6-18-17: Ribociclib + letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) with no prior endocrine therapy (ET) for ABC: CompLEEment-1 trial, preliminary results from Spanish population
Salvador, J, Ciruelos, EM, Prat, A, Jiménez-Rodríguez, B, de la Cruz, L, Martínez, N, Villanueva Vázquez, R, de Toro, R, Antón, A, Moreno, F, Alvarez, I, Gavila, J, Quiroga, V, Vicente, E, de la Haba, J, González-Santiago, S, Díaz, N, Barnadas, A, Cantos Sánchez de Ibargüen, B, Delgado, JI, Bellet, M, Gimeno, A, Sanz, S, Martin, M
Published in Cancer research (Chicago, Ill.) (15.02.2019)
Published in Cancer research (Chicago, Ill.) (15.02.2019)
Get full text
Journal Article
The importance of early identification of infusion-related reactions to monoclonal antibodies
Cáceres, Macarena C, Guerrero-Martín, Jorge, Pérez-Civantos, Demetrio, Palomo-López, Patricia, Delgado-Mingorance, Juan Ignacio, Durán-Gómez, Noelia
Published in Therapeutics and clinical risk management (01.01.2019)
Published in Therapeutics and clinical risk management (01.01.2019)
Get full text
Journal Article